Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the company’s latest ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

Merck & Co., Inc. is a global biopharmaceutical enterprise engaged in discovery, development, manufacturing, and commercialization of prescription medicines, vaccines, biologic therapies, and animal ...

On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space ...

Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, ...

Merck’s Maurice R. Hilleman Center for Vaccine Manufacturing photographed on Friday, Apr. 2, 2021, in Durham, N.C. Casey Toth ctoth@newsobserver.com In one of the biggest health care deals of 2025, ...

The Pennsylvania Department of Environmental Protection has not received complaints regarding Merck's Cherokee Plant for more than a decade.